Suppr超能文献

TOPGEAR 国际 III 期临床试验:新辅助放化疗治疗胃癌的质量保证可行性(AGITG/TROG/NHMRC CTC/EORTC/CCTG 协作组的一项多中心临床试验)

The Feasibility of Quality Assurance in the TOPGEAR International Phase 3 Clinical Trial of Neoadjuvant Chemoradiation Therapy for Gastric Cancer (an Intergroup Trial of the AGITG/TROG/NHMRC CTC/EORTC/CCTG).

机构信息

Radiation Medicine Program, Princess Margaret Cancer Centre and Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.

Trans-Tasman Radiation Oncology Group, University of Newcastle, Newcastle, New South Wales, Australia.

出版信息

Int J Radiat Oncol Biol Phys. 2023 Dec 1;117(5):1096-1106. doi: 10.1016/j.ijrobp.2023.06.011. Epub 2023 Jun 29.

Abstract

PURPOSE

The TOPGEAR phase 3 trial hypothesized that adding preoperative chemoradiation therapy (CRT) to perioperative chemotherapy will improve survival in patients with gastric cancer. Owing to the complexity of gastric irradiation, a comprehensive radiation therapy quality assurance (RTQA) program was implemented. Our objective is to describe the RTQA methods and outcomes.

METHODS AND MATERIALS

RTQA was undertaken in real time before treatment for the first 5 patients randomized to CRT from each center. Once acceptable quality was achieved, RTQA was completed for one-third of subsequent cases. RTQA consisted of evaluating (1) clinical target volume and organ-at-risk contouring and (2) radiation therapy planning parameters. Protocol violations between high- (20+ patients enrolled) and low-volume centers were compared using the Fisher exact test.

RESULTS

TOPGEAR enrolled 574 patients, of whom 286 were randomized to receive preoperative CRT and 203 (71%) were included for RTQA. Of these, 67 (33%) and 136 (67%) patients were from high- and low-volume centers, respectively. The initial RTQA pass rate was 72%. In total, 28% of cases required resubmission. In total, 200 of 203 cases (99%) passed RTQA before treatment. Cases from low-volume centers required resubmission more often (44/136 [33%] vs 13/67 [18%]; P = .078). There was no change in the proportion of cases requiring resubmission over time. Most cases requiring resubmission had multiple protocol violations. At least 1 aspect of the clinical target volume had to be adjusted in all cases. Inadequate coverage of the duodenum was most common (53% major violation, 25% minor violation). For the remaining cases, the resubmission process was triggered secondary to poor contour/plan quality.

CONCLUSIONS

In a large multicenter trial, RTQA is feasible and effective in achieving high-quality treatment plans. Ongoing education should be performed to ensure consistent quality during the entire study period.

摘要

目的

TOPGEAR 阶段 3 试验假设在围手术期化疗的基础上添加术前放化疗(CRT)将改善胃癌患者的生存率。由于胃照射的复杂性,实施了全面的放射治疗质量保证(RTQA)计划。我们的目的是描述 RTQA 方法和结果。

方法和材料

在每个中心的前 5 例接受 CRT 随机分组的患者开始治疗之前,实时进行 RTQA。一旦达到可接受的质量,就对三分之一的后续病例进行 RTQA。RTQA 包括评估(1)临床靶区和危及器官的轮廓和(2)放射治疗计划参数。使用 Fisher 精确检验比较高(20+ 例入组)和低容量中心之间的方案违规情况。

结果

TOPGEAR 共入组 574 例患者,其中 286 例随机接受术前 CRT,203 例(71%)纳入 RTQA。其中,67 例(33%)和 136 例(67%)分别来自高容量和低容量中心。初始 RTQA 通过率为 72%。共有 28%的病例需要重新提交。共有 203 例中的 200 例(99%)在治疗前通过 RTQA。低容量中心的病例重新提交的频率更高(44/136[33%]比 13/67[18%];P=0.078)。随着时间的推移,需要重新提交的病例比例没有变化。大多数需要重新提交的病例都有多个方案违规。所有病例都必须调整临床靶区的至少一个方面。十二指肠覆盖不足最为常见(53%主要违规,25%次要违规)。对于其余病例,重新提交过程是由于轮廓/计划质量差而触发的。

结论

在一项大型多中心试验中,RTQA 是可行且有效的,可以实现高质量的治疗计划。应进行持续教育,以确保整个研究期间的质量一致。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验